Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen
J. Christopher Gallagher, Warren T. Kable, David Goldgar
purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
The American Journal of Medicine
Dive into the research topics of 'Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen'. Together they form a unique fingerprint.
Progestins Medicine & Life Sciences 100%
Cortical Bone Medicine & Life Sciences 99%
Estrogens Medicine & Life Sciences 74%
Conjugated (USP) Estrogens Medicine & Life Sciences 61%
Medroxyprogesterone Acetate Medicine & Life Sciences 57%
Metacarpal Bones Medicine & Life Sciences 55%
Bone Density Medicine & Life Sciences 41%
Gallagher, J. C., Kable, W. T., & Goldgar, D. (1991). Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. The American Journal of Medicine, 90(1), 171-178. https://doi.org/10.1016/0002-9343(91)90538-9
Effect of progestin therapy on cortical and trabecular bone : comparison with estrogen. / Gallagher, J. Christopher; Kable, Warren T.; Goldgar, David.
In: The American Journal of Medicine, Vol. 90, No. 1, 01.1991, p. 171-178.
Gallagher, JC, Kable, WT & Goldgar, D 1991, 'Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen', The American Journal of Medicine, vol. 90, no. 1, pp. 171-178. https://doi.org/10.1016/0002-9343(91)90538-9
Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. The American Journal of Medicine. 1991 Jan;90(1):171-178. https://doi.org/10.1016/0002-9343(91)90538-9
Gallagher, J. Christopher ; Kable, Warren T. ; Goldgar, David. / Effect of progestin therapy on cortical and trabecular bone : comparison with estrogen. In: The American Journal of Medicine. 1991 ; Vol. 90, No. 1. pp. 171-178.
@article{45b3e19c2086474cbf6be92b71c9ac07,
title = "Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen",
abstract = "purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera{\textregistered} 20 mg, Premarin{\textregistered} 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p ",
author = "Gallagher, {J. Christopher} and Kable, {Warren T.} and David Goldgar",
journal = "American Journal of Medicine",
T1 - Effect of progestin therapy on cortical and trabecular bone
T2 - comparison with estrogen
AU - Gallagher, J. Christopher
AU - Kable, Warren T.
AU - Goldgar, David
N2 - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
AB - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
JO - American Journal of Medicine
JF - American Journal of Medicine